+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anthracycline-associated cardiotoxicity in survivors of childhood cancer



Anthracycline-associated cardiotoxicity in survivors of childhood cancer



Pediatric Cardiology 32(3): 342-353



Anthracycline chemotherapeutic agents are widely used to treat childhood cancers, helping to create an increasing population of childhood cancer survivors. Cardiac complications can occur years after exposure to anthracyclines and are a leading cause of noncancerous morbidity and mortality in this population. The mechanism of its cardiotoxicity is not completely known, although oxidative stress is believed to play a significant role. This pathway and other nonoxidative mechanisms are reviewed. Several risk factors such as age, dose, female gender, and concomitant radiation therapy are known, but the relative risks of many comorbidities such as diabetes and hypertension are not well studied. No standard, evidence-based guidelines for appropriate screening methods to detect cardiotoxicity exist. Periodic imaging with echocardiography or radionuclide angiography is appropriately recommended for long-term survivors but is of limited use during therapy. Biomarkers such as cardiac troponins and brain natriuretic peptides may aid in detecting cardiotoxicity. Studies investigating the use of agents such as angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers to treat anthracycline cardiotoxicity have shown promise, but more data are needed. Structural analogs such as epirubicin were developed to minimize cardiotoxicity but have not sufficiently reduced it. Liposome-encapsulated anthracyclines have shown a considerable decrease of cardiotoxicity in adults without sacrificing efficacy, but the data related to children are sparse. The only agent proven to be cardioprotective is the iron chelator, dexrazoxane. Studies have shown that dexrazoxane is safe and significantly reduces the incidence of cardiotoxicity. Dexrazoxane should be considered for pediatric oncology protocols using anthracyclines that include longitudinal assessment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051563291

Download citation: RISBibTeXText

PMID: 21221562

DOI: 10.1007/s00246-010-9878-3


Related references

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatric Cardiology 34(4): 826-834, 2013

Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4): 525-533, 2008

Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion in Cardiology 29(1): 103-112, 2014

Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Pediatric Cardiology 36(6): 1112-1119, 2016

Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology 7(2): 122-128, 2007

Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer. Current Cancer Therapy Reviews 8(2): 141-151, 2012

Anthracycline cardiotoxicity in survivors of childhood cancer: Clinical course, protection, and treatment. Progress in Pediatric Cardiology 36(1-2): 11-18, 2014

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circulation. Cardiovascular Imaging 6(6): 873-880, 2014

Anthracycline cardiotoxicity in long-term survivors of childhood cancer: The light is not at the end of the tunnel. Pediatric Blood and Cancer 48(7): 649-650, 2007

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatric Blood and Cancer 62(1): 123-127, 2015

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. Journal of Cancer Survivorship 8(2): 183-189, 2015

Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography 35(2): 234-240, 2017

Monitoring Survivors of Childhood AML for Anthracycline Cardiotoxicity. Aap Grand Rounds 18(6): 62-63, 2007

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?. Pediatric Hematology and Oncology 31(3): 237-252, 2015